Información del artículo
Las infecciones son la principal causa de muerte en los pacientes neutropénicos, en relación con el grado y la duración de la neutropenia, la enfermedad de base y los tratamientos recibidos. Para disminuir estas infecciones se han propuesto estrategias de profilaxis: medidas para evitar el contagio por contacto, por inhalación o por vía digestiva. Aunque la descontaminación intestinal con fluoroquinolonas ha reducido las infecciones por bacilos gramnegativos, no se recomienda su uso indiscriminado, sino reservar su utilización para pacientes de muy alto riesgo. El fluconazol como profilaxis antifúngica reduce la mortalidad, pero no modifica la incidencia de la aspergilosis invasiva. La infección por citomegalovirus debe prevenirse en los pacientes con serología negativa; en los que presentan una serología positiva con alto riesgo de enfermedad se recomienda la monitorización y el tratamiento anticipado con ganciclovir o foscarnet. Los factores de crecimiento hematopoyético reducen la duración de la neutropenia y podrían reducir la mortalidad de causa infecciosa.
Palabras clave:
Neutropenia
Infección bacteriana
Infección fúngica
Infección viral
Profilaxis
Infections are the main cause of death in neutropenic patients and are related to the degree and duration of neutropenia, the underlying disease, and the treatments received. To reduce the number of these infections, prophylactic strategies have been proposed. These strategies aim to prevent adquisition through contact, inhalation, or the gastrointestinal tract. Intestinal decontamination through fluoroquinolones has reduced Gram-negative infections but this strategy should not be used indiscriminately and should be reserved for high risk patients. Fluconazole as antifungal prophylaxis reduces mortality but does not modify the incidence of invasive aspergillosis. Cytomegalovirus infection should be prevented in patients with negative serology; in high risk patients with positive serology, monitoring and preemptive treatment with ganciclovir or foscarnet is recommended. Hematopoietic growth factors reduce the duration of neutropenia and could reduce mortality from infection.
Key words:
Neutropenia
Bacterial infection
Fungal infection
Viral infection
Prophylaxis
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. Viscoli, E. Castagnola.
Prophylaxis and Empirical Therapy in Cancer Patients.
Mandell, Douglas and Bennett's principles and practice of infectious diseases, 6th ed., WB Saunders Company, (2004),
[2.]
W. Hugues, D. Armstrong, G. Bodey, E. Bow, A. Brown, T. Calandra, et al.
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
Clin Infect Dis, 34 (2002), pp. 730-751
[3.]
G.R. Donowitz, D.G. Maki, C.J. Crnich, P.G. Pappas, K.V.I. Rolston.
Infections in the neutropenic patient. New views of an old problem.
Hematology, 1 (2001), pp. 113-139
[4.]
T. Walsh, J. Hiemenz, P. Pizzo.
Evolving risk factors for invasive fungal infections- all neutropenic patients are not the same.
Clin Infect Dis, 18 (1994), pp. 793-798
[5.]
P. Pizzo, J. Meyers.
Infections in the cancer patient.
Principles and practice of oncology, pp. 2088-2133
[6.]
P. Engervall, M. Bjorkholm.
Infections in neutropenic patients (I): aetiology.
Med Oncol, 4 (1994), pp. 251-256
[7.]
Studies of the EORTC Internacional Antimicrobial Therapy Group (IATG).
Management of infection in cancer patients.
Eur J Cancer, 38 (2002), pp. S82-S87
[8.]
Guidelines for preventing opportunistic infections among hematopoietic stem cell transplantation recipients.
Centers for Disease Control and Prevention.
Morb Mort Wkly Rep MMWR, 49 (2000), pp. 1-125
[9.]
E. Engels, J. Lau, M. Barza.
Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis.
J Clin Oncol, 16 (1998), pp. 1179-1187
[10.]
M. Cruciani, R. Rampazzo, M. Malena.
Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis.
Clin Infect Dis, 23 (1996), pp. 795-805
[11.]
J. Klastersky.
Prevention of infection in neutropenic cancer patients.
Curr Opin Oncol, 4 (1996), pp. 270-278
[12.]
J. Klastersky.
Science and pragmatism in the treatment and prevention of neutropenic infection.
J Antimicrob Chemother, 41 (1998), pp. 13-24
[13.]
B.A. Oppenheim.
The changing pattern of infection in neutropenic patients.
J Antimicrob Chemother, 41 (1998), pp. 7-11
[14.]
S. Zinner.
Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria.
Clin Infect Dis, 3 (1999), pp. 490-494
[15.]
W. Hugues, D. Armstrong, G. Bodey, A. Brown, J.E. Edwards, R. Feld, et al.
1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever.
Clin Infect Dis, 25 (1997), pp. 551-573
[16.]
J. Garner.
Guideline for isolation precautions in hospitals.
Am J Infect Control, 24 (1996), pp. 24-31
[17.]
D. Pittet, J. Boyce.
Revolutioning hand hygiene in health-care settings: guidelines revisited.
Lancet Infect Dis, 3 (2003), pp. 269-270
[18.]
J. Boyce, D. Pittet.
Guideline for hand hygiene in health–care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force.
Am J Infect Control, 30 (2002), pp. 1S-46S
[19.]
P. Muñoz, A. Burillo, E. Bouza.
Environmental suveillance and other control neasures in the prevention of nosocomial fungal infections.
Clin Microbiol Infect, 7 (2001), pp. 38-45
[20.]
J. Goodley, Y. Clayton, R. Hay.
Environmental sampling for Aspergillosis during building construction on a hospital site.
J Hosp Infect, 26 (1994), pp. 27-35
[21.]
Guidelines for environmental infection control in health-care facilities: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC).
Centers for Disease Control and Prevention.
Morb Mort Wkly Rep MMWR, 52 (2003), pp. 1-44
[22.]
G.J. Cadwell.
Evaluation of high efficiency filters.
J Parenter Drug Assoc, 32 (1978), pp. 182-187
[23.]
T. Hahn, K. Cummings, A. Michalek, B. Lipman, B. Segal, P.J. McCarthy.
Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies.
Infect Control Hosp Epidemiol, 23 (2002), pp. 525-531
[24.]
A. Leenders, A. Van Belkum, M. Behrendt, A. Luijendjk, H. Verbrugh.
Density and molecular epidemiology of Aspergillus in air and relationship to outbreaks of Aspergillus infection.
J Clin Microbiol, 37 (1999), pp. 1752-1757
[25.]
M. Comet, V. Levy, L. Fleury, J. Lortholary, S. Barquins, M. Coureul.
Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation.
Infect Control Hosp Epidemiol, 20 (1999), pp. 508-513
[26.]
I. Oren, N. Haddad, R. Filkelstein, J. Rowe.
Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters.
Am J Hematol, 66 (2001), pp. 257-262
[27.]
Y. Qjan, K. Willeke, S. Grinshùn, J. Donnelly, C. Coffey.
Performance of N95 respirators: filtration efficiendy for airborne microbial and inert particles.
Am Ind Hyg Assoc J, 59 (1998), pp. 128-132
[28.]
K. Moody, M. Charlson, J. Finlay.
The neutropenic diet: what's the evidence?.
J Pediatr Hematol Oncol, 24 (2002), pp. 717-721
[29.]
American Society of Heating RaA-CEI.
ASHRAE guideline 12-2000: minimizing the risk of legionellosis associated with building water systems.
ASHRAE, 12 (2000), pp. 1-6
[30.]
Guidelines for prevention of nosocomial pneumonia.
Centers for Disease Control and Prevention.
Morb Mort Wkly Rep MMWR, 46 (1997), pp. 1-79
[31.]
V. Tjan-Heijnen, P. Postmus, A. Ardizzoni, C. Manegold, J. Burghouts, J. Van Meerbeeck, et al.
Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.
Ann Oncol, 10 (2001), pp. 1359-1368
[32.]
M. Lew, K. Kehoe, J. Ritz.
Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation.
Transplantation, 51 (1991), pp. 630-636
[33.]
G.I. EORTC.
Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer.
JAMA, 19 (1994), pp. 1183-1189
[34.]
A. Gafter-Gvili, A. Fraser, M. Paul, L. Leibovici.
Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
Ann Intern Med, 42 (2005), pp. 979-995
[35.]
G. Bucaneve, A. Micozzi, F. Menichetti, P. Martino, M. Dionisi, G. Martinelli, et al.
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
N Engl J Med, 353 (2005), pp. 977-987
[36.]
P. Richard, M. Delangle, D. Merrien.
Fluoroquinolone use and fluoroquinolone resistance: Is there an association?.
Clin Infect Dis, 19 (1994), pp. 54-59
[37.]
S. Yeh, C. Chiu, W. Lo.
Low infectious morbidity in patients with heavily pretreated hematological malignancies receiving autologous peripheral blood stem cell transplantation without antimicrobial prophylaxis.
Ann Hematol, 82 (2003), pp. 24-29
[38.]
E. Bow, M. Laverdiere, N. Lussier.
Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized controlled clinical trials.
Cancer, 94 (2002), pp. 3230-3236
[39.]
O. Cornely, A. Ullmann, M. Karthaus.
Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies.
Blood, 101 (2003), pp. 3365-3372
[40.]
Y. Kanda, R. Yamamoto, A. Chizuka, T. Hamaki, M. Suguro, C. Arai, et al.
Prophylactic action of oral fluconazole against fungal infection in neutropenic patients.
Cancer, 89 (2000), pp. 1611-1625
[41.]
M. Rozenberg-Arska, A. Dekker, J. Branger, J. Verhoef.
A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia.
J Antimicrob Chemother, 3 (1991), pp. 369-376
[42.]
J. Goodman, D. Winston, R. Greenfield, P. Chandrasekar, B. Fox, H. Kaizer, et al.
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.
N Engl J Med, 326 (1992), pp. 845-851
[43.]
D. Winston, P. Chandrasekar, H. Lazarus, J. Goodman, J. Silber, H. Horowitz, et al.
Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial.
Ann Intern Med, 118 (1993), pp. 495-503
[44.]
F. Menichetti, A. Del Favero, P. Martino, G. Bucaneve, A. Micozzi, D. D’Antonio, et al.
Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B.
Ann Intern Med, 120 (1994), pp. 913-918
[45.]
C. Rotstein, E. Bow, M. Laverdiere, S. Ioannou, D. Carr, N. Moghaddam.
Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy.
Clin Infect Dis, 40 (1999), pp. 331-340
[46.]
K. Marr, K. Seidel, M. Slavin.
Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo- controlled trial.
Blood, 96 (2000), pp. 2055-2061
[47.]
H. Johansen, P. Gotzsche.
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.
Cochrane Database Syst Rev, 2 (2002),
[48.]
Centers for Disease Control and Prevention.
Guidelines for preventing opportunistic infections among hematopoietic stem cell transplantation recipients.
Biol Blood Marrow Transplant, 6 (2000), pp. 659-733
[49.]
A. Wald, W. Leisenring, J. Van Burik, R. Bowden.
Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation.
J Infect Dis, 175 (1997), pp. 1459-1466
[50.]
H. Prentice, C. Kibbler, A. Prentice.
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
Br J Haematol, 110 (2000), pp. 273-284
[51.]
M. MacMillan, J. Goodman, T. DeFor.
Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy.
Am J Med, 112 (2002), pp. 369-379
[52.]
G. Mattiuzzi, H. Kantarjian, S. O’Brien, D. Kontoyiannis, F. Giles, X. Zhou, et al.
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Cancer, 100 (2004), pp. 568-573
[53.]
J. Tollemar, O. Ringden, S. Andersson, B. Sundberg, P. Ljungman, G. Tyden.
Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.
Bone Marrow Transplant, 6 (1993), pp. 577-582
[54.]
S. Kelsey, J. Goldman, S. McCann, A. Newland, J. Scarffe, B. Oppenheim, et al.
Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.
Bone Marrow Transplant, 2 (2005), pp. 163-168
[55.]
M. Wood.
Viral infections in neutropenia-current problems and chemotherapeutic control.
J Antimicrob Chemother, 41 (1998), pp. 81-93
[56.]
R. Saral, W. Burns, O. Laskin, G. Santos, P. Lietman.
Acyclovir prophylaxis of herpes simplex virus infections: humana randomized, double-blind, placebocontrolled trial in bone marrow transplant recipients.
N Engl J Med, 305 (1981), pp. 63-67
[57.]
M. Bishop, S. Tarantolo, R. Geller.
A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
Blood, 96 (2000), pp. 80-85
[58.]
Y. Lalami, M. Paesmans, M. Aoun, R. Muñoz-Bermeo, K. Reuss, S. Cherifi, et al.
A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia.
Support Care Cancer, 10 (2004), pp. 725-730
[59.]
L. Sung, P. Nathan, B. Lange, J. Beyene, G. Buchanan.
Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
J Clin Oncol, 22 (2004), pp. 3350-3356
[60.]
O. Howard, O. James.
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.
J Clin Oncol, 18 (2000), pp. 3558
[61.]
S. Wolff, J. Fay, R. Herzig, J. Greer, S. Dummer, R. Brown, et al.
High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy: a Study of the American Bone Marrow Transplant Group.
Ann Intern Med, 118 (1993), pp. 937-942
Copyright © 2005. Elsevier España S.L.. Todos los derechos reservados
